Search results
Results from the WOW.Com Content Network
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
Antipsychotics by class Generic name Brand names Chemical class ATC code ... Atypical antipsychotics; Amoxapine: Asendin, Asendis, Defanyl, Demolox: dibenzoxazepine:
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]
A large meta-analysis of 38 trials of antipsychotic drugs in schizophrenia with acute psychotic episodes showed an effect size of about 0.5. [37] There is little or no difference in efficacy among approved antipsychotic drugs, including both first- and second-generation agents. [23] [38] The efficacy of such drugs is suboptimal. Few patients ...
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. [3] [4] [5] It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia.
Recently, the FDA required the manufacturers of some atypical antipsychotics to include a warning about the risk of hyperglycemia and Type II diabetes with atypical antipsychotics. Some evidence suggests that ziprasidone does not cause insulin resistance to the degree of other atypical antipsychotics, such as olanzapine. Weight gain is also ...